SEC Form 4 · accession 0001662252-18-000107
Xenetic Biosciences, Inc. · XBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Eric Callaway
Director
Period of report
Nov 28, 2018
Accepted (ET)
Nov 30, 2018 · 5:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534525
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $3.05 | Nov 28, 2018 | A | 25,000 | A | — | Nov 28, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The Options vest in equal quarterly installments over the twelve-month period commencing on the grant date.